Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: Cost-effectiveness in the US

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3085-3096

  Tunis, Sandra L ^a   Minshall, Michael E ^a   St Charles, Meaghan ^a   Pandya, Bhavik J ^b   Baran, Robert W ^b  

^a IMS Consulting Services   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Cost effectiveness; Diabetes complications; Diabetes mellitus; Dyslipidemia; Health care economics; Pioglitazone; Rosiglitazone

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; ECONOMIC EVALUATION; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RISK FACTOR; SENSITIVITY ANALYSIS; SIMULATION; UNITED STATES;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; UNITED STATES;

EID: 67649389576     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802434874     Document Type: Article

References (53)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20
4. The UK Prospective Diabetes Study Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
6. Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-877 (Pubitemid 40767979)
7. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA, US Department of Health and Human Services, 2005.
8. Kaur J, Singh P, Sowers J. Diabetes and cardiovascular disease. Am J Ther 2002;9:510-515
9. Jacobs M, Kleisli T, Pio J, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-269 (Pubitemid 41539788)
10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35
11. Mody R, Kalsekar I, Kavookjian J, et al. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications 2007;21:75-83 (Pubitemid 46304268)
12. Derosa G, Cicero A, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelvemonth, multicenter, double-blind, randomized, controlled, parallel- group trial. Clin Ther 2004;26:744-754 (Pubitemid 38736964)
13. Goldberg R, Kendall D, Deeg M, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554 (Pubitemid 40923063)
14. Palmer A, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-40 (Pubitemid 39349906)
15. Palmer A, Roze S, Valentine W, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-26 (Pubitemid 39349905)
16. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Man Care 2008;14:131-140
17. Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33 (Pubitemid 351160873)
18. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. J Man Care Pharm 2006;12:726-735 (Pubitemid 47394434)
19. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES) Data. Hyattsville, MD: US Department of Health and Human Services, 2000.
20. Kannel W, Wolf P, Benjamin E, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9 (Pubitemid 28507114)
21. Phillips S, Whisnant J, O'Fallon W, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clinic Proceedings 1990;65:344-359 (Pubitemid 20124303)
22. Miller C, Phillips L, Tate M, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:444-448 (Pubitemid 30185784)
23. Harris M. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-758 (Pubitemid 30414188)
24. Brandle M, Zhou H, Smith B, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304 (Pubitemid 36993316)
25. Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America. 2nd edn. Bethesda, MD, USA: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda MD, USA, 1995.
26. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arc Intern Med 1992;152:610-616
27. Massing M, Foley K, Sueta C, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care. 2003;26:991-997
28. McFarlane S, Jacober S, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-723 (Pubitemid 41071193)
29. O'Brien J, Patrick A, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-1038
30. US Department of Labor, Bureau of Labor Statistics, Consumer price index for the healthcare sector, 2006.
31. St. Anthony's DRG Guidebook. A comprehensive resource to the DRG classification system, Reston, VA, USA. Medicode, 2001.
32. Shearer A, Scuffham P, Gordois A, et al. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-2310 (Pubitemid 36993317)
33. Bullano M, Al-Zakwani I, Fisher M, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-298 (Pubitemid 40469905)
34. Drug Topics Redbook. Medical Economics Company, ed. Montvale, NJ, USA. Thomson PDR, 2004.
35. Golan L, Birkmeyer J, Welch H. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-667 (Pubitemid 29517951)
36. O'Brien J, Shomphe L, Kavanagh P. Direct medical costs of complications from type 2 diabetes in the US. Diabetes Care 1998;21:296-308 (Pubitemid 28368519)
37. Kantor J, Margolis D. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:347-351 (Pubitemid 32290859)
38. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Dec Making 2002;22:340-349 (Pubitemid 34791321)
39. Tengs T, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
40. Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003. Australian Institute of Health and Welfare, 2007. Available from http://www.aihw.gov.au/bod/index.cfm [Last accessed 7 July 2007].
41. Carrington A, Mawdsley S, Morley M. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996;32:19-25 (Pubitemid 26191382)
42. National Institute for Clinical Excellence (NICE). Technology appraisal guidance on the use of long-acting insulin analogues, No.53, December, 2002. Available from http://www.nice.org.uk/guidance/[Last accessed 15 May 2007].
43. American Diabetes Association.Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265
44. Tarn T, Smith M. Pharmacoeconomics guidelines around the world. ISPOR Connections 2004;10:5-15
45. 1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20:53-58
46. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-679 (Pubitemid 33135349)
47. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-1781 (Pubitemid 34761059)
48. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163 (Pubitemid 32156199)
49. Halpern E, Weinstein M, Hunink M, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-322 (Pubitemid 30470727)
50. Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
51. Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002;20:31-42 (Pubitemid 34564436)
52. Baigent C, Landray MJ, Wheeler DC. Cardiovascular and survival paradoxes in dialysis patients: misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Seminars in Dialysis 2007;20:498-503
53. Tilden DP, Mariz S, O'Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54 (Pubitemid 46072367)